<DOC>
	<DOCNO>NCT00872469</DOCNO>
	<brief_summary>The WOMAN trial large pragmatic randomise double-blind , placebo control trial quantify effect early administration tranexamic acid death , hysterectomy relevant outcome . 20,000 adult woman , delivery clinically diagnose postpartum haemorrhage , eligible responsible doctor reason substantially uncertain whether use antifibrinolytic agent . Additionally , TWO nest study conduct subset woman trial participant . The first nest study ( ETAC ) aim evaluate effect tranexamic acid ( TXA ) marker coagulation 400 woman randomise WOMAN trial . The second nested study ( ETAPLAT ) aim evaluate haemostatic effect antithrombotic effect TXA 128 woman randomise WOMAN trial .</brief_summary>
	<brief_title>World Maternal Antifibrinolytic Trial</brief_title>
	<detailed_description>BACKGROUND : Each year , worldwide 530,000 woman die cause related pregnancy childbirth . Almost ( 99 % ) death low middle income country . Obstetric haemorrhage lead cause maternal mortality account one quarter one third death , occur postpartum period . About 14 million mother develop postpartum haemorrhage ( PPH ) year 1-2 % die , average interval onset death 2 4 hour . Obstetric haemorrhage also important cause maternal mortality high income country account 13 % maternal death . Anti-fibrinolytic agent widely use surgery reduce blood loss need blood transfusion . A systematic review randomise controlled trial anti-fibrinolytic agent elective surgery show tranexamic acid ( TXA ) reduce risk blood transfusion relative 39 % ( RR 0.61 , 95 % CI 0.54 0.69 ) . In require transfusion , TXA reduce transfused blood volume 1.1 unit ( 95 % CI 0.64 1.59 ) . Anti-fibrinolytic agent also reduce need re-operation due bleeding ( RR=0.52 : 95 % CI 0.40 0.69 ) . There evidence increase risk thrombotic event . TXA significantly reduce uterine blood loss woman menorrhagia `` recommended consideration '' treatment intractable postpartum haemorrhage UK . However , present little reliable evidence randomise trial effectiveness TXA treatment PPH . A systematic review randomise trial TXA PPH conduct applicant identify three trial prophylactic use TXA , include total 460 participant . Although significant reduction average postpartum blood loss woman treat TXA [ weight mean reduction 96 ml ( 95 % CI 76ml 109ml ) ] quality trial poor . None adequate allocation concealment even aggregate trial small assess effect TXA clinically important end point mortality , hysterectomy thrombotic side effect . The recently update PPH treatment guideline prepare World Health Organization ( WHO ) state TXA may use treatment PPH measure fail , point quality evidence recommendation base low recommends clinical trial TXA PPH conduct . AIM : The WOMAN Trial aim determine effect early administration tranexamic acid ( TXA ) death hysterectomy woman clinical diagnosis postpartum haemorrhage . The effect TXA need surgical intervention , blood transfusion , risk non-fatal vascular event ( either haemorrhagic occlusive ) , use health service breastfeed also assess . OUTCOME : Outcomes collect 42 day randomisation , discharge death ( whichever occurs first ) . TEST PRODUCT , DOSE AND MODE OF ADMINISTRATION : A first dose Tranexamic acid ( 1 gram intravenous injection ) give soon possible randomisation . If clinically indicate due continue bleeding , second dose Tranexamic acid ( 1 gram intravenous injection ) give within 4 hour randomisation . REFERENCE THERAPY , DOSE AND MODE OF ADMINISTRATION : A placebo ( sodium chloride 0.9 % ) match active drug administer way active product . A placebo justified trial woman PPH receive treatment clinically indicate . Tranexamic acid/placebo give additional treatment . SETTING : This trial co-ordinated LSHTM conduct hospital low , middle high income country . It likely patient recruitment country high rate mortality morbidity postpartum haemorrhage . DURATION OF TREATMENT AND PARTICIPATION : The first dose give immediately randomisation . If require , second dose give 24 hour randomisation . No trial treatment give 24 hour randomisation . Participation end discharge , death 42 day post randomisation whichever occur first . CRITERIA FOR EVALUATION : All patient randomly assign one treatment analyse together , regardless whether complete receive treatment intention treat basis . NESTED STUDY 1 : Effect tranexamic acid coagulation sample 400 participant WOMAN trial ( ETAC ) . This aim evaluate effect TXA marker coagulation sample WOMAN trial participant . Standard coagulation parameter ( platelet , ﬁbrinogen , PT aPTT time D-dimer ) ROTEM® parameter measure vitro activation tissue factor ( EXTEM ) inhibition aprotinin ( APTEM ) determine ( maximum lysis , maximum strength [ Maximal Clot Firmness ( MCF ) ] , time start waveform reach 2mm baseline [ Clotting Time ( CT ) ] , time 2mm baseline 20mm baseline [ Clot Formation Time ( CFT ) ] , time lysis [ CLT ( 10 % difference MCF ) ] , time Maximum strength [ MCF-t ] , Clot elasticity [ MCE ] ) . NESTED STUDY 2 : This aim assess haemostatic antithrombotic effect TXA sample 128 participant WOMAN Trial ( ETAPLAT ) . Platelet function , thrombin generation , fibrinogen level , D-Dimer coagulation factor V , VIII vWF assess .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<mesh_term>Antifibrinolytic Agents</mesh_term>
	<criteria>All legally adult woman postpartum haemorrhage follow vaginal caesarean section delivery clinical diagnosis postpartum haemorrhage . The clinical diagnosis PPH may base follow : Blood loss vaginal delivery &gt; 500 mL OR &gt; 1,000 mL caesarean section OR blood loss sufficient compromise haemodynamic status woman The fundamental eligibility criterion responsible clinician 's 'uncertainty ' whether use antifibrinolytic agent particular woman postpartum haemorrhage . Women responsible doctor considers clear indication antifibrinolytic therapy randomise . Women consider clear contraindication antifibrinolytic therapy randomise . Where responsible clinician substantially uncertain whether use antifibrinolytic , woman eligible randomisation consider trial . There prespecified exclusion criterion .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Postpartum haemorrhage</keyword>
	<keyword>randomise control trial</keyword>
	<keyword>tranexamic acid</keyword>
	<keyword>antifibrinolytic</keyword>
</DOC>